0001535955
false
0001535955
2023-08-10
2023-08-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported):
August
10, 2023
LIPOCINE
INC.
(Exact
name of registrant as specified in its charter)
Commission
File No. 001-36357
Delaware |
|
99-0370688 |
(State
or other jurisdiction
of
incorporation) |
|
(IRS
Employer
Identification
Number) |
675
Arapeen Drive, Suite 202
Salt
Lake City, Utah 84108
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (801) 994-7383
Former
name or former address, if changed since last report: Not Applicable
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13©(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.0001 per share |
|
LPCN |
|
The
NASDAQ Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events
On
August 10, 2023, the Company issued a press release announcing financial and operational results for the quarter ended June 30, 2023.
The press release is filed as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
The
following exhibits are filed with this report:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
LIPOCINE
INC. |
|
|
|
|
Date: |
August
10, 2023 |
By: |
/s/
Mahesh V. Patel |
|
|
|
Mahesh
V. Patel |
|
|
|
President
and Chief Executive Officer |
Exhibit 99.1
Lipocine Announces Financial
Results for the Second Quarter Ended June 30, 2023
SALT LAKE CITY, August 10,
2023 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today
announced financial results for the second quarter and six months ended June 30, 2023, and provided a corporate update.
Clinical Program Highlights
Neuroactive Steroids
● |
Lipocine announced
positive topline results from a pilot pharmacokinetics (“PK”) bridge study of LPCN 1154 (oral brexanolone). Lipocine is developing
LPCN 1154 for postpartum depression (“PPD”) |
|
|
|
○ |
The bridge study results demonstrated comparative pharmacokinetics of LPCN 1154 to an approved IV brexanolone |
|
|
|
|
○ |
The study identified a dosing regimen of LPCN 1154 to be tested in a single confirmatory pivotal PK study required for NDA filing |
|
|
|
|
○ |
LPCN 1154 treatment was well-tolerated with no hypoxia or sedation-related adverse events |
LPCN 1148 in liver cirrhosis
● |
Lipocine announced positive topline results from its Phase 2 proof-of-concept (“POC”) study evaluating LPCN 1148 in cirrhosis |
|
|
|
○ |
Study met primary endpoint: treatment with LPCN 1148 increased L3 skeletal muscle index (L3-SMI) relative to placebo (P <0.01) |
|
|
|
|
○ |
Fewer hepatic encephalopathy (HE) events of grade >1 in the LPCN 1148 treatment arm relative to placebo (P < 0.05) |
|
|
|
|
○ |
More patients on LPCN 1148 reported symptom improvement compared to placebo (P < 0.05) |
|
|
|
|
○ |
LPCN 1148 was well-tolerated, with AE rates and severities similar to placebo |
|
|
|
|
○ |
Lipocine plans to meet with the FDA to discuss the development path to NDA filing |
● |
Posters on LPCN 1148 and LPCN 1144 were presented at the European Association for the Study of the Liver (EASL) Congress 2023, in Vienna, Austria, June 21 – 24, 2023 |
Quarter Ended June 30, 2023 Financial Results
Lipocine reported a net loss of $3.6 million, or ($0.68)
per diluted share, for the three months ended June 30, 2023, compared with a net loss of $2.6 million or ($0.61) per diluted share, in
the three months ended June 30, 2022.
Lipocine did not recognize any revenue during the
three months ended June 30, 2023. During the three months ended June 30, 2022, we recognized revenue related to a non-refundable cash
fee of $0.5 million received from Antares for consideration of a 90-day extension for Antares to exercise its option to license LPCN 1111.
Research and development
expenses were $2.5 million and $2.9 million, respectively, for the three months ended June 30, 2023, and 2022. The decrease in research
and development expenses year over year was a result of a decrease in costs related to our LPCN 1154 clinical studies, a decrease in lab
supplies, small equipment and other research and development costs, a decrease in contract research organization expense and outside consulting
costs related to the completion of our LPCN 1144 LiFT study in 2022, a decrease related to our completed PK and food effect studies for
LPCN 1107, and a decrease in LPCN 1111 scale up costs. These decreases were offset by an increase in contract research organization expense
related to the LPCN 1148 Phase 2 POC study in male subjects with cirrhosis, an increase in personnel related costs and an increase in
TLANDO related costs.
General and administrative
expenses were $1.4 million and $1.1 million, respectively, for the three months ended June 30, 2023, and 2022. The increase in general
and administrative expenses year over year was primarily due to an increase in professional and legal fees related to our reverse stock
split and other general and administrative expenses, an increase in estimated franchise taxes resulting from our reverse stock split,
as well as increases in business development fees, personnel salaries and benefits, market research activities and director fees. These
increases were offset by a decrease resulting from professional fees incurred in our recruitment of two additional directors in 2022 and
a decrease in corporate insurance expense.
As of June 30, 2023, Lipocine
had $25.8 million of unrestricted cash, cash equivalents and marketable investment securities compared to $32.5 million at December 31,
2022.
Six Months Ended June 30, 2023 Financial Results
Lipocine reported a net loss of $7.4 million, or ($1.44)
per diluted share, for the six months ended June 30, 2023, compared with a net loss of $6.1 million or ($1.20) per diluted share, in the
six months ended June 30, 2022.
Lipocine recognized license
revenue of approximately $55,000 during the six months ended June 30, 2023. We recognized revenue related to a non-refundable cash fee
of $0.5 million received from Antares for consideration of a 90-day extension for Antares to exercise its option to license LPCN 1111
during the six months ended June 30, 2022.
Research and development
expenses were $5.6 million and $4.8 million, respectively, for the six months ended June 30, 2023, and 2022. The increase in research
and development expenses year over year resulted from an increase in contract research organization expense related to the Phase 2 POC
study of LPCN 1148, an increase in costs related to LPCN 1154 clinical studies, an increase in personnel salaries and benefits resulting
from the hiring of additional personnel, and an increase in TLANDO related expenses. These increases were offset by a decrease in contract
research organization expense and outside consulting costs related to the completion of our LPCN 1144 LiFT study 2022, a decrease related
to LPCN 1111 scale up costs in 2022, a decrease related to the completion of our LPCN 1107 PK and food effect studies in 2022 and a decrease
in expenses for lab supplies, small equipment and other research and development activities.
General and administrative
expenses were $2.7 million and $2.4 million, respectively, for the six months ended June 30, 2023, and 2022. The increase in general and
administrative expenses year over year was primarily due to an increase in professional and legal fees related to our reverse stock split
and other general and administrative expenses, an increase in business development fees, an increase in estimated franchise taxes, an
increase in director fees, an increase in personnel salaries and benefit costs, and an increase in market research activities. These increases
were offset by a decrease resulting from professional fees incurred in our recruitment of two additional directors in 2022 and a decrease
in corporate insurance expense.
For more information on Lipocine’s
financial results for the three and six months ended June 30, 2023, refer to Form 10Q filed with the SEC.
About Lipocine
Lipocine is a biopharmaceutical
company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated
products for CNS disorders. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnering.
Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile
which target large addressable markets with significant unmet medical needs.
Lipocine’s clinical
development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101 for the
potential treatment of epilepsy and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management
of symptoms associated with liver cirrhosis. Lipocine is exploring partnering opportunities for LPCN 1107, our candidate for prevention
of preterm birth, LPCN1154, for rapid relief of postpartum depression, LPCN 1148, for the management of decompensated cirrhosis, LPCN
1144, our candidate for treatment of non-cirrhotic NASH, and LPCN 1111, a once-a-day therapy candidate for testosterone replacement therapy
(TRT). TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA
for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information,
please visit www.lipocine.com.
Forward-Looking Statements
This release contains “forward-looking
statements” that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include
statements that are not historical facts regarding our product development efforts, the application of our proprietary platform in developing
new treatments for CNS disorders, our product candidates and related clinical trials, our development of and filing of a NDA with the
FDA for LPCN 1148,and the potential uses and benefits of our product candidates. Investors are cautioned that all such forward-looking
statements involve risks and uncertainties, including, without limitation, the risks that we may not be successful in developing product
candidates to treat CNS disorders, we may not have sufficient capital to complete the development processes for our product candidates,
we may not be able to enter into partnerships or other strategic relationships to monetize our non-core assets, the FDA will not approve
any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations
and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt
of regulatory approvals and our ability to utilize a streamlined approval pathway for LPCN 1154, the results and timing of clinical trials,
patient acceptance of Lipocine’s products, the manufacturing and commercialization of Lipocine’s products, and other risks
detailed in Lipocine’s filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q,
all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking
statements contained in this release, except as required by law.
For further information:
Krista Fogarty
Phone: (801) 994-7383
kf@lipocine.com
Investors:
PJ Kelleher
Phone: (617) 430-7879
pkelleher@lifesciadvisors.com
LIPOCINE INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(Unaudited)
|
|
June 30, |
|
|
December 31, |
|
|
|
2023 |
|
|
2022 |
|
Assets |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
5,014,695 |
|
|
$ |
3,148,496 |
|
Marketable investment securities |
|
|
20,775,275 |
|
|
|
29,381,410 |
|
Accrued interest income |
|
|
24,230 |
|
|
|
80,427 |
|
Contract asset - current portion |
|
|
579,428 |
|
|
|
579,428 |
|
Prepaid and other current assets |
|
|
690,900 |
|
|
|
945,319 |
|
|
|
|
|
|
|
|
|
|
Total current assets |
|
|
27,084,528 |
|
|
|
34,135,080 |
|
|
|
|
|
|
|
|
|
|
Contract asset - non-current portion |
|
|
3,252,500 |
|
|
|
3,252,500 |
|
Property and equipment, net of accumulated depreciation of $1,166,441 and $1,153,530 respectively |
|
|
122,679 |
|
|
|
131,589 |
|
Other assets |
|
|
23,753 |
|
|
|
23,753 |
|
|
|
|
|
|
|
|
|
|
Total assets |
|
$ |
30,483,460 |
|
|
$ |
37,542,922 |
|
|
|
|
|
|
|
|
|
|
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
517,587 |
|
|
$ |
600,388 |
|
Accrued expenses |
|
|
1,309,595 |
|
|
|
1,077,738 |
|
Total current liabilities |
|
|
1,827,182 |
|
|
|
1,678,126 |
|
|
|
|
|
|
|
|
|
|
Warrant liability |
|
|
104,267 |
|
|
|
229,856 |
|
Total liabilities |
|
|
1,931,449 |
|
|
|
1,907,982 |
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders' equity: |
|
|
|
|
|
|
|
|
Common stock, par value $0.0001 per share, 200,000,000 shares authorized; 5,235,166 issued and 5,234,830 outstanding |
|
|
8,852 |
|
|
|
8,852 |
|
Additional paid-in capital |
|
|
219,443,674 |
|
|
|
219,112,164 |
|
Treasury stock at cost, 336 shares |
|
|
(40,712 |
) |
|
|
(40,712 |
) |
Accumulated other comprehensive loss |
|
|
(15,812 |
) |
|
|
(20,321 |
) |
Accumulated deficit |
|
|
(190,843,991 |
) |
|
|
(183,425,043 |
) |
|
|
|
|
|
|
|
|
|
Total stockholders' equity |
|
|
28,552,011 |
|
|
|
35,634,940 |
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders' equity |
|
$ |
30,483,460 |
|
|
$ |
37,542,922 |
|
LIPOCINE INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
and Comprehensive Loss
(Unaudited)
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues: |
|
$ |
- |
|
|
$ |
500,000 |
|
|
$ |
54,990 |
|
|
$ |
500,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
2,515,211 |
|
|
|
2,898,012 |
|
|
|
5,621,521 |
|
|
|
4,785,965 |
|
General and administrative |
|
|
1,440,394 |
|
|
|
1,129,519 |
|
|
|
2,727,708 |
|
|
|
2,373,205 |
|
Total operating expenses |
|
|
3,955,605 |
|
|
|
4,027,531 |
|
|
|
8,349,229 |
|
|
|
7,159,170 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss |
|
|
(3,955,605 |
) |
|
|
(3,527,531 |
) |
|
|
(8,294,239 |
) |
|
|
(6,659,170 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest and investment income |
|
|
379,521 |
|
|
|
69,877 |
|
|
|
749,991 |
|
|
|
111,453 |
|
Interest expense |
|
|
- |
|
|
|
(7,568 |
) |
|
|
- |
|
|
|
(27,098 |
) |
Unrealized gain on warrant liability |
|
|
27,455 |
|
|
|
583,445 |
|
|
|
125,589 |
|
|
|
205,457 |
|
Gain on litigation settlement liability |
|
|
- |
|
|
|
250,000 |
|
|
|
- |
|
|
|
250,000 |
|
Total other income, net |
|
|
406,976 |
|
|
|
895,754 |
|
|
|
875,580 |
|
|
|
539,812 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss before income tax expense |
|
|
(3,548,629 |
) |
|
|
(2,631,777 |
) |
|
|
(7,418,659 |
) |
|
|
(6,119,358 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax expense |
|
|
- |
|
|
|
- |
|
|
|
(200 |
) |
|
|
(200 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
|
(3,548,629 |
) |
|
|
(2,631,777 |
) |
|
|
(7,418,859 |
) |
|
|
(6,119,558 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of Series B preferred stock dividend |
|
|
- |
|
|
|
- |
|
|
|
(89 |
) |
|
|
- |
|
Net loss attributable to common shareholders |
|
$ |
(3,548,629 |
) |
|
$ |
(2,631,777 |
) |
|
$ |
(7,418,948 |
) |
|
$ |
(6,119,558 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic loss per share attributable to common stock |
|
$ |
(0.68 |
) |
|
$ |
(0.50 |
) |
|
$ |
(1.42 |
) |
|
$ |
(1.17 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding, basic |
|
|
5,234,830 |
|
|
|
5,234,141 |
|
|
|
5,234,830 |
|
|
|
5,228,608 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted loss per share attributable to common stock |
|
$ |
(0.68 |
) |
|
$ |
(0.61 |
) |
|
$ |
(1.44 |
) |
|
$ |
(1.20 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding, diluted |
|
|
5,234,830 |
|
|
|
5,263,389 |
|
|
|
5,234,830 |
|
|
|
5,262,993 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(3,548,629 |
) |
|
$ |
(2,631,777 |
) |
|
$ |
(7,418,859 |
) |
|
$ |
(6,119,558 |
) |
Net unrealized gain (loss) on available-for-sale securities |
|
|
(19,053 |
) |
|
|
(17,491 |
) |
|
|
4,509 |
|
|
|
(66,891 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive loss |
|
$ |
(3,567,682 |
) |
|
$ |
(2,649,268 |
) |
|
$ |
(7,414,350 |
) |
|
$ |
(6,186,449 |
) |
v3.23.2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Apr 2024 to May 2024
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From May 2023 to May 2024